Specific N-Linked Glycosylation Patterns in Areas of Necrosis in Tumor Tissues.

N-linked glycans formalin-fixed tissues glycosylation hypoxia mass spectrometry imaging necrosis

Journal

International journal of mass spectrometry
ISSN: 1387-3806
Titre abrégé: Int J Mass Spectrom
Pays: Netherlands
ID NLM: 101137096

Informations de publication

Date de publication:
Mar 2019
Historique:
entrez: 30 4 2019
pubmed: 30 4 2019
medline: 30 4 2019
Statut: ppublish

Résumé

Tissue necrosis is a form of cell death common in advanced and aggressive solid tumors, and is associated with areas of intratumoral chronic ischemia. The histopathology of necrotic regions appear as a scaffold of cellular membrane remnants, reflective of the hypoxia and cell degradation events associated with this cellular death pathway. Changes in the glycosylation of cell surface proteins is another common feature of cancer progression. Using a recently developed mass spectrometry imaging approach to evaluate N-linked glycan distributions in human formalin-fixed clinical cancer tissues, differences in the glycan structures of regions of tumor, stroma and necrosis were evaluated. While the structural glycan classes detected in the tumor and stromal regions are typically classified as high mannose or branched glycans, the glycans found in necrotic regions displayed limited branching, contained sialic acid modifications and lack fucose modifications. While this phenomenon was initially classified in breast cancer tissues, it has been also seen in cervical, thyroid and liver cancer samples. These changes in glycosylation within the necrotic regions could provide further mechanistic insight to necrotic changes in cancer tissue and provide new research directions for identifying prognostic markers of necrosis.

Identifiants

pubmed: 31031563
doi: 10.1016/j.ijms.2018.01.002
pmc: PMC6483403
mid: NIHMS935685
doi:

Types de publication

Journal Article

Langues

eng

Pagination

69-76

Subventions

Organisme : NCI NIH HHS
ID : R21 CA186799
Pays : United States

Références

J Biol Chem. 2002 Jan 4;277(1):424-31
pubmed: 11679593
Mol Cell Biol. 2004 Jul;24(13):5914-22
pubmed: 15199146
Cancer Res. 2007 Jan 1;67(1):218-26
pubmed: 17210702
Chemotherapy. 2007;53(4):233-56
pubmed: 17595539
Cell Death Differ. 2008 Feb;15(2):386-97
pubmed: 18007661
Cancer Sci. 2010 Mar;101(3):586-93
pubmed: 20085584
Curr Pharm Des. 2010 Jan;16(1):56-68
pubmed: 20214618
Future Oncol. 2011 Oct;7(10):1223-35
pubmed: 21992733
Nat Rev Mol Cell Biol. 2012 Jun 22;13(7):448-62
pubmed: 22722607
Anal Chem. 2013 Oct 15;85(20):9799-806
pubmed: 24050758
Biochem J. 2014 Jan 1;457(1):79-87
pubmed: 24099577
Proteomics. 2014 Mar;14(4-5):525-46
pubmed: 24339177
J Proteome Res. 2014 May 2;13(5):2297-313
pubmed: 24702160
Biochim Biophys Acta. 2014 Sep;1844(9):1437-52
pubmed: 24830338
PLoS One. 2014 Sep 03;9(9):e106255
pubmed: 25184632
Adv Cancer Res. 2015;126:11-51
pubmed: 25727145
Adv Cancer Res. 2015;126:53-135
pubmed: 25727146
Adv Cancer Res. 2015;126:345-82
pubmed: 25727153
Methods Mol Biol. 2015;1273:3-15
pubmed: 25753699
Anal Chem. 2015 Jun 16;87(12):5947-5956
pubmed: 25993305
J Cancer Res Clin Oncol. 2016 Feb;142(2):453-63
pubmed: 26094047
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
J Am Soc Mass Spectrom. 2016 Feb;27(2):244-54
pubmed: 26407555
Biomolecules. 2015 Oct 15;5(4):2554-72
pubmed: 26501333
Glycoconj J. 2016 Jun;33(3):285-96
pubmed: 26612686
Oncotarget. 2016 Jun 7;7(23):35478-89
pubmed: 27007155
Anal Chem. 2016 Jun 7;88(11):5904-13
pubmed: 27145236
Anal Chem. 2016 Aug 2;88(15):7745-53
pubmed: 27373711
Mol Cell Proteomics. 2016 Sep;15(9):3003-16
pubmed: 27412689
Glycobiology. 2017 Jan;27(1):3-49
pubmed: 27558841
Sci Rep. 2016 Oct 13;6:35374
pubmed: 27734938
Electrophoresis. 2017 Jan;38(1):162-189
pubmed: 27757981
Cancer Res. 2017 Jun 1;77(11):2903-2913
pubmed: 28416487
Nat Med. 1997 Oct;3(10):1089-95
pubmed: 9334719

Auteurs

Danielle A Scott (DA)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Kim Norris-Caneda (K)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Laura Spruill (L)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Evelyn Bruner (E)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Yuko Kono (Y)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Peggi M Angel (PM)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Anand S Mehta (AS)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Richard R Drake (RR)

Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, South Carolina.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.
Department of Medicine, University of California San Diego, San Diego, California.

Classifications MeSH